CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...
Phase 3
Budapest, Hungary and 155 other locations
first-line treatment of participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...
Phase 3
Budapest, Hungary and 203 other locations
after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponso...
Phase 3
Budapest, Hungary and 195 other locations
cancer in the pancreas.Adult participants with metastatic pancreatic adenocarcinoma will receive Test Product (TP) and Reference Product (RP...
Phase 1
Budapest, Hungary and 35 other locations
GEJ adenocarcinoma in adult participants.The primary hypotheses of this study are that pembrolizumab plus chemotherapy is superior to place...
Phase 3
Budapest, Hungary and 214 other locations
The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for ca...
Phase 3
Budapest, Hungary and 199 other locations
Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemo...
Phase 3
Budapest, Hungary and 148 other locations
The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...
Phase 3
Budapest, Hungary and 348 other locations
in in microsatellite instability-high/Defective mismatch repair (MSI-H/dMMR) locally advanced unresectable or metastatic gastric /GEJ adenocarcinomas...
Phase 1, Phase 2
Budapest, Hungary and 39 other locations
The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
Phase 1, Phase 2
Budapest, Hungary and 114 other locations
Clinical trials
Research sites
Resources
Legal